|
WO1998001162A2
(en)
*
|
1996-07-09 |
1998-01-15 |
The Johns Hopkins University |
Gene delivery system
|
|
IT1289608B1
(it)
*
|
1997-02-05 |
1998-10-15 |
Angelini Ricerche Spa |
Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
|
|
US6593369B2
(en)
|
1997-10-20 |
2003-07-15 |
Vivus, Inc. |
Methods, compositions, and kits for enhancing female sexual desire and responsiveness
|
|
US7087236B1
(en)
|
1998-09-01 |
2006-08-08 |
Merrion Research I Limited |
Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
|
|
EP1117378A2
(en)
|
1998-10-05 |
2001-07-25 |
The Penn State Research Foundation |
Compositions and methods for enhancing receptor-mediated cellular internalization
|
|
US20050153926A1
(en)
*
|
1998-12-04 |
2005-07-14 |
Adams Christopher P. |
Method for the immobilization of oligonucleotides
|
|
US7273618B2
(en)
*
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
|
US8114850B2
(en)
|
1999-04-08 |
2012-02-14 |
Advanced Cancer Therapeutics, Llc |
Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
|
|
US7960540B2
(en)
|
1999-04-08 |
2011-06-14 |
Advanced Cancer Therapeutics, Llc |
Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
|
|
EP1181304B1
(en)
|
1999-04-08 |
2007-10-10 |
Antisoma Research Limited |
Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
|
|
EP2289550A3
(en)
|
2000-01-27 |
2012-02-15 |
MedImmune, LLC |
Ultra high affinity neutralizing antibodies
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6262020B1
(en)
*
|
2000-02-15 |
2001-07-17 |
Alphamed Pharmaceuticals Corp. |
Topical wound therapeutic compositions
|
|
PT1259547E
(pt)
*
|
2000-03-01 |
2012-10-15 |
Medimmune Inc |
Anticorpos recombinantes de alta potência e método para a sua produção
|
|
CA2401239A1
(en)
*
|
2000-03-03 |
2001-09-13 |
Valentis, Inc. |
Improved poloxamer and poloxamine compositions for nucleic acid delivery
|
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
|
US20040009940A1
(en)
*
|
2000-10-20 |
2004-01-15 |
Coleman Michael E. |
Gene delivery formulations and methods for treatment of ischemic conditions
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
|
CA2430039C
(en)
|
2000-11-28 |
2014-01-28 |
Medimmune, Inc. |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
|
ES2727425T3
(es)
|
2000-12-12 |
2019-10-16 |
Medimmune Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
US6848197B2
(en)
*
|
2001-04-18 |
2005-02-01 |
Advanced Inhalation Research, Inc. |
Control of process humidity to produce large, porous particles
|
|
US20030134810A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Chris Springate |
Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
|
|
WO2003046144A2
(en)
*
|
2001-11-26 |
2003-06-05 |
Molecular Reflections, Inc. |
Microscale immobilization of molecules using a hydrogel and methods of use thereof
|
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
WO2004010935A2
(en)
*
|
2002-07-25 |
2004-02-05 |
Medimmune, Inc. |
Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
|
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
|
ATE502051T1
(de)
|
2002-10-16 |
2011-04-15 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
|
US7483738B2
(en)
*
|
2002-11-29 |
2009-01-27 |
Power Paper Ltd. |
Combination stimulating and exothermic heating device and method of use thereof
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
JP2007525149A
(ja)
|
2003-01-13 |
2007-09-06 |
マクロジェニクス，インコーポレーテッド |
可溶性ＦｃγＲ融合タンパク質およびその使用法
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2004078213A1
(ja)
*
|
2003-03-06 |
2004-09-16 |
Chikako Nishigori |
対象物質導入用組成物及び対象物質導入方法
|
|
JP4764818B2
(ja)
|
2003-04-11 |
2011-09-07 |
メディミューン，エルエルシー |
組換えｉｌ−９抗体およびその使用
|
|
US20050123550A1
(en)
*
|
2003-05-12 |
2005-06-09 |
Laurent Philippe E. |
Molecules enhancing dermal delivery of influenza vaccines
|
|
WO2004112702A2
(en)
*
|
2003-06-13 |
2004-12-29 |
Advanced Inhalation Research, Inc. |
Low dose pharmaceutical powders for inhalation
|
|
ES2458636T3
(es)
|
2003-08-18 |
2014-05-06 |
Medimmune, Llc |
Humanización de anticuerpos
|
|
PL1684782T3
(pl)
|
2003-10-03 |
2016-03-31 |
Thorn Bioscience Llc |
Sposób synchronizacji owulacji dla zsynchronizowanego rozmnażania bez wykrywania rui
|
|
DK1761248T3
(da)
*
|
2004-03-19 |
2012-09-03 |
Rodos Biotarget Gmbh |
Kulhydrat-deriverede liposomer bestemt til at målrettes mod cellulære kulhydrat-genkende-domæner af CTL/CTLD-lecitiner samt intracellulær afgivelse af terapeutisk aktive sammensætninger
|
|
CA2574977C
(en)
*
|
2004-07-29 |
2010-01-26 |
X-Sten, Corp. |
Spinal ligament modification devices
|
|
WO2006018899A1
(ja)
*
|
2004-08-17 |
2006-02-23 |
Bml, Inc. |
検出用器具を用いた検出方法
|
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
US20060115485A1
(en)
*
|
2004-10-29 |
2006-06-01 |
Medimmune, Inc. |
Methods of preventing and treating RSV infections and related conditions
|
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
|
EP1868650B1
(en)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
JP2008546805A
(ja)
|
2005-06-23 |
2008-12-25 |
メディミューン，エルエルシー |
最適な凝集および断片化プロフィールを有する抗体製剤
|
|
US20070003528A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Paul Consigny |
Intracoronary device and method of use thereof
|
|
CN103172738A
(zh)
*
|
2005-06-30 |
2013-06-26 |
Abbvie公司 |
Il-12/p40结合蛋白
|
|
EP1912575B1
(en)
|
2005-07-29 |
2011-01-19 |
Vertos Medical, Inc. |
Percutaneous tissue excision devices
|
|
SI2573114T1
(sl)
|
2005-08-10 |
2016-08-31 |
Macrogenics, Inc. |
Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
|
EP2500356A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
NZ597168A
(en)
|
2005-08-19 |
2013-07-26 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
|
KR101434935B1
(ko)
|
2005-11-30 |
2014-10-01 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
|
|
CN117903302A
(zh)
|
2005-11-30 |
2024-04-19 |
Abbvie 公司 |
抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
|
|
US7942830B2
(en)
|
2006-05-09 |
2011-05-17 |
Vertos Medical, Inc. |
Ipsilateral approach to minimally invasive ligament decompression procedure
|
|
DK2029173T3
(en)
|
2006-06-26 |
2016-11-07 |
Macrogenics Inc |
FC-RIIB-specific antibodies and methods of use thereof
|
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
|
ES2661032T3
(es)
|
2006-09-08 |
2018-03-27 |
Abbvie Bahamas Ltd. |
Proteínas de unión a interleucina-13
|
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
AU2007234612B2
(en)
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
US10280211B2
(en)
|
2007-05-04 |
2019-05-07 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Engineered rabbit antibody variable domains and uses thereof
|
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
|
CN107226864A
(zh)
|
2007-06-21 |
2017-10-03 |
宏观基因有限公司 |
共价双抗体及其用途
|
|
US7678764B2
(en)
|
2007-06-29 |
2010-03-16 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations for use at elevated temperatures
|
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
CN101801405A
(zh)
|
2007-08-07 |
2010-08-11 |
先进科技及再生医学有限责任公司 |
包含于酸性水溶液中的gdf-5的蛋白质配方
|
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
WO2009129101A1
(en)
*
|
2008-04-14 |
2009-10-22 |
Advanced Technologies And Regenerative Medicine, Llc |
Liquid buffered gdf-5 formulations
|
|
EP2899209A1
(en)
|
2008-04-29 |
2015-07-29 |
Abbvie Inc. |
Dual Variable Domain Immunoglobulins and uses thereof
|
|
WO2009136382A2
(en)
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
|
US9035027B2
(en)
|
2008-06-03 |
2015-05-19 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
RU2010153578A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойными вариабельными доменами и их применение
|
|
EP2321422A4
(en)
|
2008-07-08 |
2013-06-19 |
Abbvie Inc |
PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
|
|
EP2310049A4
(en)
|
2008-07-08 |
2013-06-26 |
Abbvie Inc |
PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF
|
|
USD621939S1
(en)
|
2008-10-23 |
2010-08-17 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD619253S1
(en)
|
2008-10-23 |
2010-07-06 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD619252S1
(en)
|
2008-10-23 |
2010-07-06 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD610259S1
(en)
|
2008-10-23 |
2010-02-16 |
Vertos Medical, Inc. |
Tissue modification device
|
|
USD611146S1
(en)
|
2008-10-23 |
2010-03-02 |
Vertos Medical, Inc. |
Tissue modification device
|
|
JP2012510821A
(ja)
*
|
2008-12-04 |
2012-05-17 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
EP3482769B1
(en)
|
2008-12-19 |
2024-05-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
BRPI1007371A2
(pt)
*
|
2009-01-29 |
2018-03-27 |
Abbott Lab |
proteínas de ligação a il-1
|
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
PL2421545T3
(pl)
|
2009-04-23 |
2018-05-30 |
Jbs United Animal Health Ii Llc |
Sposób i kompozycja do synchronizacji czasu inseminacji
|
|
DK2437767T3
(en)
|
2009-06-01 |
2015-09-28 |
Medimmune Llc |
MOLECULES WITH EXTENDED half-lives and uses thereof
|
|
BRPI1015234A2
(pt)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
regiões fc projetadas para conjugação sítio específica.
|
|
JP5762408B2
(ja)
|
2009-08-13 |
2015-08-12 |
クルセル ホランド ベー ヴェー |
ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
|
|
AU2010286518C1
(en)
|
2009-08-29 |
2015-08-27 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
|
BR112012004710A2
(pt)
|
2009-09-01 |
2016-08-16 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e uso das mesmas
|
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
AU2010303415B2
(en)
|
2009-10-07 |
2015-02-19 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
KR20140015139A
(ko)
|
2009-10-15 |
2014-02-06 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US8420083B2
(en)
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
KR20120118002A
(ko)
|
2009-12-08 |
2012-10-25 |
애보트 게엠베하 운트 콤파니 카게 |
망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
|
|
PE20130580A1
(es)
|
2010-03-02 |
2013-06-02 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
|
CN102892430A
(zh)
|
2010-03-17 |
2013-01-23 |
雅培研究有限公司 |
抗神经生长因子（ngf）抗体组合物
|
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
|
EA201291181A1
(ru)
|
2010-05-06 |
2013-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
|
|
AU2011249783B9
(en)
|
2010-05-06 |
2014-11-06 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies
|
|
PH12012502226A1
(en)
|
2010-05-14 |
2013-02-04 |
Abbvie Inc |
Il-1 binding proteins
|
|
US20130150286A1
(en)
|
2010-06-25 |
2013-06-13 |
Jean-Claude Sirard |
Methods and pharmaceutical compositions for the treatment of respiratory tract infections
|
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
KR101896124B1
(ko)
|
2010-07-09 |
2018-09-07 |
얀센 백신스 앤드 프리벤션 비.브이. |
항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
EP3533803B1
(en)
|
2010-08-14 |
2021-10-27 |
AbbVie Inc. |
Anti-amyloid-beta antibodies
|
|
PL3333188T3
(pl)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Przeciwciała anty-ngf i ich zastosowanie
|
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
|
DK2606070T3
(en)
|
2010-08-20 |
2017-03-27 |
Novartis Ag |
Antibodies for the epidermal growth factor receptor 3 (HER3)
|
|
AU2011293253B2
(en)
|
2010-08-26 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
|
JP6009455B2
(ja)
|
2010-12-21 |
2016-10-19 |
アッヴィ・インコーポレイテッド |
Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
|
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
|
RS57324B1
(sr)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
|
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
HK1198328A1
(zh)
|
2011-07-13 |
2015-04-02 |
Abbvie Inc. |
使用抗il-13抗體治療哮喘的方法和組合物
|
|
JP2014526886A
(ja)
|
2011-07-15 |
2014-10-09 |
モルフォシス・アー・ゲー |
マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
|
|
EP2756094B1
(en)
|
2011-08-15 |
2017-12-27 |
Medlmmune, LLC |
Anti-b7-h4 antibodies and their uses
|
|
CN104203978A
(zh)
|
2011-10-24 |
2014-12-10 |
艾伯维股份有限公司 |
针对硬化蛋白的免疫结合剂
|
|
EP2771029A4
(en)
|
2011-10-25 |
2015-07-01 |
Onclave Therapeutics Ltd |
ANTIBODY FORMULATIONS AND METHOD THEREFOR
|
|
JP6243345B2
(ja)
|
2011-12-05 |
2017-12-06 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
|
|
UY34486A
(es)
|
2011-12-05 |
2013-07-31 |
Novartis Ag |
Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
|
|
MX356933B
(es)
|
2011-12-14 |
2018-06-20 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
|
|
JP6342812B2
(ja)
|
2011-12-14 |
2018-06-13 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
鉄関連障害を診断および治療するための組成物および方法
|
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
|
SG10202006762PA
(en)
|
2012-01-27 |
2020-08-28 |
Abbvie Deutschland |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
JP6321633B2
(ja)
|
2012-06-04 |
2018-05-09 |
ノバルティス アーゲー |
部位特異的標識法およびそれによって生成される分子
|
|
AU2013271564A1
(en)
|
2012-06-06 |
2014-12-04 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
|
WO2014071074A2
(en)
|
2012-11-01 |
2014-05-08 |
Abbvie Inc. |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
|
HK1216428A1
(zh)
|
2012-11-09 |
2016-11-11 |
辉瑞公司 |
血小板衍生生长因子b之特异性抗体及其组合物和用途
|
|
KR20150095715A
(ko)
|
2012-11-28 |
2015-08-21 |
제이비에스 유나이티드 애니멀 헬스투 엘엘씨 |
미경산돈에서 수정 시간을 동기화하기 위한 방법
|
|
SG11201504764SA
(en)
|
2012-12-19 |
2015-07-30 |
Amplimmune Inc |
Anti-human b7-h4 antibodies and their uses
|
|
RU2650756C2
(ru)
|
2012-12-21 |
2018-04-17 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела к h7cr
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
EA201591465A1
(ru)
|
2013-02-08 |
2015-12-30 |
АйАрЭм ЭлЭлСи |
Специфичные участки для модификации антител для получения иммуноконъюгатов
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3564384A1
(en)
|
2013-03-14 |
2019-11-06 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
|
EP2970947A4
(en)
|
2013-03-14 |
2016-10-12 |
Abbott Lab |
RECOMBINANT HCV NS3 ANTIGENS AND THEIR MUTANTS FOR ENHANCED ANTIBODY DETECTION
|
|
CA2906421C
(en)
|
2013-03-14 |
2022-08-16 |
George J. Dawson |
Hcv antigen-antibody combination assay and methods and compositions for use therein
|
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
EP2968590B1
(en)
|
2013-03-15 |
2018-09-05 |
Novartis AG |
Antibody drug conjugates
|
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
|
SG11201509618QA
(en)
|
2013-05-24 |
2015-12-30 |
Medimmune Llc |
Anti-b7-h5 antibodies and their uses
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
ES2891755T3
(es)
|
2013-06-06 |
2022-01-31 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
|
JP6581572B2
(ja)
|
2013-06-07 |
2019-09-25 |
デューク ユニバーシティ |
補体因子ｈ阻害薬
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP3046935B1
(en)
|
2013-09-17 |
2020-12-16 |
University Health Network (UHN): Technology Development And Commercialization |
Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
|
|
US10287572B2
(en)
|
2013-11-01 |
2019-05-14 |
Regents Of The University Of Minnesota |
Protein scaffolds and methods of use
|
|
TWI736515B
(zh)
|
2013-11-13 |
2021-08-21 |
美商輝瑞大藥廠 |
類腫瘤壞死因子之配體１ａ之專一性抗體及其組合物及用途
|
|
TW201536320A
(zh)
|
2013-12-02 |
2015-10-01 |
Abbvie Inc |
治療骨性關節炎之組合物及方法
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
|
US10100115B2
(en)
|
2014-02-14 |
2018-10-16 |
Macrogenics, Inc. |
Methods for the treatment of vascularizing cancers
|
|
EP3110974A4
(en)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
WO2015138337A1
(en)
|
2014-03-09 |
2015-09-17 |
Abbvie, Inc. |
Compositions and methods for treating rheumatoid arthritis
|
|
SG11201606850QA
(en)
|
2014-03-12 |
2016-09-29 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
PE20161211A1
(es)
|
2014-03-21 |
2016-11-27 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
|
|
EP3888690A3
(en)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
AU2015266797C1
(en)
|
2014-05-29 |
2019-04-04 |
Macrogenics, Inc. |
Tri-Specific Binding Molecules that specifically bind to multiple Cancer Antigens and methods of use thereof
|
|
RU2016146994A
(ru)
*
|
2014-06-16 |
2018-07-16 |
ЗОИТИС СЕРВИСЕЗ ЭлЭлСи |
Интравагинальные композиции, содержащие GnRH
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
US20170291956A1
(en)
|
2014-07-16 |
2017-10-12 |
David Livingston |
HER3 Inhibition in Low-grade Serous Ovarian Cancers
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
CA2954599A1
(en)
|
2014-08-12 |
2016-02-18 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
|
AP2017009823A0
(en)
|
2014-09-26 |
2017-03-31 |
Macrogenics Inc |
Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
|
|
CA2969847A1
(en)
|
2014-12-10 |
2016-06-16 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
CN114230664B
(zh)
|
2014-12-11 |
2025-01-03 |
皮埃尔法布雷医药公司 |
抗c10orf54抗体及其用途
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
CN108367003B
(zh)
|
2014-12-12 |
2022-01-21 |
麻省总医院 |
乳腺癌脑转移的治疗
|
|
TW201639596A
(zh)
|
2015-01-24 |
2016-11-16 |
艾伯維有限公司 |
用於治療牛皮癬性關節炎之組合物及方法
|
|
EP3250601A4
(en)
|
2015-01-26 |
2018-07-11 |
MacroGenics, Inc. |
Multivalent molecules comprising dr5-binding domains
|
|
WO2016120828A1
(en)
|
2015-01-30 |
2016-08-04 |
Novartis Ag |
Treatment of breast cancer by m-csf antagonist
|
|
KR20250005465A
(ko)
|
2015-03-03 |
2025-01-09 |
키맵 리미티드 |
항체, 용도 및 방법
|
|
CN113603782A
(zh)
|
2015-05-29 |
2021-11-05 |
艾伯维公司 |
抗cd40抗体及其用途
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
WO2017015619A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
|
MA42542B1
(fr)
|
2015-07-30 |
2021-09-30 |
Macrogenics Inc |
Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
|
|
MX2018003040A
(es)
|
2015-09-11 |
2018-04-11 |
Abbvie Inc |
Metodos para el tratamiento de formas recurrentes de esclerosis multiple.
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
KR20250079249A
(ko)
|
2015-10-08 |
2025-06-04 |
마크로제닉스, 인크. |
암 치료를 위한 조합 치료법
|
|
US11849741B2
(en)
|
2015-10-20 |
2023-12-26 |
Savage River, Inc. |
Meat-like food products
|
|
EP3365369A1
(en)
|
2015-10-23 |
2018-08-29 |
Pfizer Inc |
Anti-il-2 antibodies and compositions and uses thereof
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
EP3909983A1
(en)
|
2015-12-02 |
2021-11-17 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
|
JP6955507B2
(ja)
|
2015-12-14 |
2021-10-27 |
マクロジェニクス，インコーポレーテッド |
Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
RU2754369C2
(ru)
|
2016-03-02 |
2021-09-01 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
|
|
KR102514317B1
(ko)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
|
|
EP3464372A1
(en)
|
2016-06-01 |
2019-04-10 |
AbbVie Inc. |
Anti-repulsive guidance molecule a (rgma) antagonistic antibodies for treating spinal cord injury and pain
|
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
AU2017279539A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-B7-H3 antibodies and antibody drug conjugates
|
|
IL300274A
(en)
|
2016-06-08 |
2023-04-01 |
Abbvie Inc |
Antibodies against B7–H3 and conjugates of drug and antibody
|
|
EP3471754A1
(en)
|
2016-06-20 |
2019-04-24 |
Kymab Limited |
Anti-pd-l1 antibodies
|
|
US20200148750A1
(en)
|
2016-07-21 |
2020-05-14 |
Emory University |
Ebola Virus Antibodies and Binding Agents Derived Therefrom
|
|
DK3509506T3
(da)
|
2016-09-07 |
2021-05-25 |
Vertos Medical Inc |
Fremgangsmåder og instrumenter til perkutan lateral rydningsresektion
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3544628A4
(en)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1BB BINDING PROTEINS AND THEIR USES
|
|
EP3554533B1
(en)
|
2016-12-13 |
2021-06-09 |
Emory University |
Polypeptides for managing viral infections
|
|
CA3047115A1
(en)
|
2016-12-16 |
2018-06-21 |
Bluefin Biomedicine, Inc. |
Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
|
|
JOP20190155A1
(ar)
|
2016-12-21 |
2019-06-23 |
Novartis Ag |
مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
|
|
EP3558368B1
(en)
|
2016-12-23 |
2025-11-12 |
MacroGenics, Inc. |
Adam9-binding molecules, and methods of use thereof
|
|
EP3574017A1
(en)
|
2017-01-27 |
2019-12-04 |
Kymab Limited |
Anti-opg antibodies
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
US11932694B2
(en)
|
2017-04-19 |
2024-03-19 |
Bluefin Biomedicine, Inc. |
Anti-VTCN1 antibodies and antibody drug conjugates
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
AU2018277838C1
(en)
|
2017-05-31 |
2025-08-07 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
|
US11542331B2
(en)
|
2017-06-06 |
2023-01-03 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
|
|
CA3066918A1
(en)
|
2017-06-12 |
2018-12-20 |
Bluefin Biomedicine, Inc. |
Anti-il1rap antibodies and antibody drug conjugates
|
|
SG11202003930YA
(en)
|
2017-12-01 |
2020-05-28 |
Pfizer |
Anti-cxcr5 antibodies and compositions and uses thereof
|
|
EP3717510A2
(en)
|
2017-12-01 |
2020-10-07 |
Novartis AG |
Polyomavirus neutralizing antibodies
|
|
AU2019217207B2
(en)
|
2018-02-12 |
2025-12-18 |
Diabetes-Free, Inc. |
Improved antagonistic anti-human CD40 monoclonal antibodies
|
|
CA3093772C
(en)
|
2018-03-12 |
2024-04-16 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
|
KR102826439B1
(ko)
|
2018-03-29 |
2025-06-26 |
화이자 인코포레이티드 |
Lfa3 변이체 및 그의 조성물 및 용도
|
|
US10640576B2
(en)
|
2018-04-10 |
2020-05-05 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
CN119490583A
(zh)
|
2018-05-31 |
2025-02-21 |
诺华股份有限公司 |
乙型肝炎抗体
|
|
MX2020012495A
(es)
|
2018-06-01 |
2021-02-15 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas.
|
|
US12172986B2
(en)
|
2018-06-01 |
2024-12-24 |
Eisai R&D Management Co., Ltd |
Splicing modulator antibody-drug conjugates and methods of use
|
|
AR115571A1
(es)
|
2018-06-20 |
2021-02-03 |
Novartis Ag |
Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
|
|
CA3111339A1
(en)
|
2018-07-10 |
2020-01-16 |
Rush University Medical Center |
Use of immunomodulators to control infection and stimulate healing in normal and diabetic wounds
|
|
JP2021531007A
(ja)
|
2018-07-20 |
2021-11-18 |
ピエール、ファーブル、メディカマン |
Ｖｉｓｔａに対する受容体
|
|
MX2021002690A
(es)
|
2018-09-07 |
2021-05-12 |
Pfizer |
Anticuerpos anti-avb8 y composiciones y usos de los mismos.
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
US12492250B2
(en)
|
2018-09-28 |
2025-12-09 |
Emory University |
suPAR and prediction and treatment of acute kidney injury
|
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
|
JP7463366B2
(ja)
|
2018-11-20 |
2024-04-08 |
タケダ ワクチン，インコーポレイテッド |
新規の抗ジカウイルス抗体及びその使用
|
|
PE20211473A1
(es)
|
2018-12-13 |
2021-08-05 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
|
|
WO2020128863A1
(en)
|
2018-12-19 |
2020-06-25 |
Novartis Ag |
Anti-tnf-alpha antibodies
|
|
CR20210324A
(es)
|
2018-12-21 |
2021-07-14 |
Novartis Ag |
Anticuerpos anti-pmel 17 y conjugados de los mismos
|
|
EP3911739A1
(en)
|
2019-01-16 |
2021-11-24 |
University Of Rochester |
Improvement of epithelial or endothelial barrier function
|
|
KR102563319B1
(ko)
|
2019-03-08 |
2023-08-03 |
앱티스 주식회사 |
위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
|
|
EP3947419A4
(en)
|
2019-04-01 |
2023-05-24 |
Rush University Medical Center |
REAGENTS AND ASSAYS USING MODIFIED INTEGRIND DOMAINS
|
|
KR20220010527A
(ko)
|
2019-05-20 |
2022-01-25 |
노파르티스 아게 |
친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
|
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
|
US11572414B2
(en)
|
2019-11-07 |
2023-02-07 |
Eisai R&D Management Co., Ltd. |
Eribulin antibody-drug conjugates and methods of use
|
|
EP4093508A1
(en)
|
2020-01-24 |
2022-11-30 |
Pfizer Inc. |
Anti-e-selectin antibodies, compositions and methods of use
|
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
JP2023523760A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
免疫グロブリン変異体
|
|
CN116096758A
(zh)
|
2020-05-01 |
2023-05-09 |
诺华股份有限公司 |
工程化免疫球蛋白
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
US20210371503A1
(en)
|
2020-05-29 |
2021-12-02 |
University Of Cologne |
Neutralizing antibodies against sars-related coronavirus
|
|
AU2021284401A1
(en)
|
2020-06-05 |
2023-01-05 |
Eisai R&D Management Co., Ltd. |
Anti-BCMA antibody-drug conjugates and methods of use
|
|
CN115803085A
(zh)
|
2020-06-27 |
2023-03-14 |
新月生物科学 |
新型细胞代谢调节化合物及用途
|
|
BR112023005980A2
(pt)
|
2020-10-09 |
2023-05-02 |
Childrens Medical Center |
Anticorpos cd1a e seus usos
|
|
GB202017058D0
(en)
|
2020-10-27 |
2020-12-09 |
Kymab Ltd |
Antibodies and uses thereof
|
|
EP4240494A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
MX2023005353A
(es)
|
2020-11-06 |
2023-05-22 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
|
EP4240765A2
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Antibody fc variants
|
|
WO2022112942A2
(en)
|
2020-11-24 |
2022-06-02 |
Novartis Ag |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2022122993A1
(en)
|
2020-12-11 |
2022-06-16 |
Boehringer Ingelheim International Gmbh |
Formulation for multi-purpose application
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
GB202101125D0
(en)
|
2021-01-27 |
2021-03-10 |
Kymab Ltd |
Antibodies and uses thereof
|
|
BR112023021475A2
(pt)
|
2021-04-16 |
2023-12-19 |
Novartis Ag |
Conjugados anticorpo-fármaco e métodos para produzir os mesmos
|
|
US20250011428A1
(en)
|
2021-10-28 |
2025-01-09 |
Novartis Ag |
Engineered fc variants
|
|
GB202117111D0
(en)
|
2021-11-26 |
2022-01-12 |
Kymab Ltd |
Antibodies for use as therapeutics against bacterial infections
|
|
AU2022400238A1
(en)
|
2021-12-01 |
2024-07-11 |
Universität Zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
|
EP4190810A1
(en)
|
2021-12-01 |
2023-06-07 |
Universität zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
|
US12138243B2
(en)
|
2021-12-31 |
2024-11-12 |
Crescenta Biosciences |
Antiviral use of FABP4 modulating compounds
|
|
CN119072493A
(zh)
|
2022-04-26 |
2024-12-03 |
诺华股份有限公司 |
靶向il-13和il-18的多特异性抗体
|
|
US12465342B2
(en)
|
2022-06-16 |
2025-11-11 |
Vertos Medical, Inc. |
Integrated instrument assembly
|
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
|
JP2025525959A
(ja)
|
2022-08-05 |
2025-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
脳腫瘍を治療するためのトランスフェリン受容体結合タンパク質
|
|
JP2025525969A
(ja)
|
2022-08-05 |
2025-08-07 |
ヤンセン バイオテツク，インコーポレーテツド |
脳腫瘍を治療するためのｃｄ９８結合構築物
|
|
KR20250134734A
(ko)
|
2022-12-16 |
2025-09-11 |
페온 테라퓨틱스 리미티드 |
Cub 도메인-함유 단백질 1(cdcp1)에 대한 항체 및 이의 용도
|
|
WO2024160721A1
(en)
|
2023-01-30 |
2024-08-08 |
Kymab Limited |
Antibodies
|
|
EP4669667A2
(en)
|
2023-02-24 |
2025-12-31 |
Universität zu Köln |
SARS-CoV-2 Neutralizing Antibodies
|
|
EP4484445A1
(en)
|
2023-06-26 |
2025-01-01 |
Universität zu Köln |
Hcmv neutralizing antibodies
|
|
WO2025003381A1
(en)
|
2023-06-28 |
2025-01-02 |
Universität Zu Köln |
Neutralizing human monoclonal antibodies against p. aeruginosa
|
|
WO2025262564A1
(en)
|
2024-06-17 |
2025-12-26 |
Pfizer Inc. |
Use of anti-cxcr5 antibodies
|